TY - JOUR
T1 - Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis
T2 - a 3-year longitudinal study
AU - Stępień, Adam
AU - Chalimoniuk, Małgorzata
AU - Lubina-Dąbrowska, Natalia
AU - Chrapusta, Stanisław J
AU - Galbo, Henrik
AU - Langfort, Józef
N1 - Copyright © 2013 S. Karger AG, Basel.
PY - 2013
Y1 - 2013
N2 - Interferon (IFN)β treatment is a mainstay of relapsing-remitting multiple sclerosis (RRMS) immunotherapy. Its efficacy is supposedly a consequence of impaired trafficking of inflammatory cells into the central nervous system and modification of the proinflammatory/antiinflammatory cytokine balance. However, the effects of long-term monotherapy using various IFNβ preparations on cytokine profiles and the relevance of these effects for the therapy outcome have not yet been elucidated.
AB - Interferon (IFN)β treatment is a mainstay of relapsing-remitting multiple sclerosis (RRMS) immunotherapy. Its efficacy is supposedly a consequence of impaired trafficking of inflammatory cells into the central nervous system and modification of the proinflammatory/antiinflammatory cytokine balance. However, the effects of long-term monotherapy using various IFNβ preparations on cytokine profiles and the relevance of these effects for the therapy outcome have not yet been elucidated.
U2 - 10.1159/000348701
DO - 10.1159/000348701
M3 - Journal article
C2 - 23711618
SN - 1021-7401
VL - 20
SP - 213
EP - 222
JO - NeuroImmunoModulation
JF - NeuroImmunoModulation
IS - 4
ER -